A Phase 2 interventional study of LY3549492 and Placebo in Healthy, sponsored by Eli Lilly and Company. Terminated at 21 sites in 2 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 280 studies in Body Weight with a site in United States — 33 open to participants now, 50 under way, 6 of them phase 3. Body Weight · United States.
Among the 280 studies in Body Weight with a site in United States, this one is the 238th largest by enrollment of the 242 interventional ones that give a count, is one of 10 that started in 2025, is one of 15 in phase 2, and was the 259th registered.
658 studies on the registry are indexed under Body Weight; 77 are open to participants now.
Browse Body Weight studies →33 of the 280 studies in Body Weight with a site in United States are open now. Recruiting first, the newest first:
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
Viking Therapeutics, Inc. · Sites in United States
Ages 18+
Amgen · Sites in United States, Canada
Ages 18+
Northwestern University · Sites in United States
Ages 18+ · Healthy volunteers
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Body Weight studies recruiting now, 22 (41%) set no upper age limit and 30 (56%) stop at 75 or younger; 6 take children under 18; 16 take healthy volunteers.
This study: 55 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
280 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 22 · Phase 3 22 · Phase 4 15
First in 1998; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 71 across 501 interventional studies indexed under Body Weight.
Median enrollment 65 across the 242 interventional studies, 100 across the 37 observational. Of the 212 that completed or were terminated, 75 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 280 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Body Weight — fewer than ten, so there is no comparison to draw.
16 of the studies in Body Weight with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT06864208The Miriam HospitalAddressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes: Randomized Pilot Trial | 2026-12 |
| NCT06314009Endeavor HealthBeyond MARS: Magnetic Resonance Study: A Novel Assessment of Placental Perfusion During Pregnancy | 2026-12 |
| NCT06252922Pennington Biomedical Research CenterDiet-Induced Changes in GEnetic Material | 2026-12-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 280 studies in Body Weight with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2).
Participation in the study will last about 13 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have:
Have any of the following cardiovascular conditions within 12 months prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were planned to receive 15 milligrams (mg) LY3549492 orally once daily for 48 weeks.
Drug: LY3549492
Participants were planned to receive 60 mg LY3549492 orally once daily for 48 weeks.
Drug: LY3549492
Participants were planned to receive matching placebo orally once daily for 48 weeks.
Drug: Placebo
Administered orally
Administered orally
Number of Participants With One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Time frame: Baseline through Week 48
Percent Change From Baseline in Body Weight
Time frame: Baseline, Week 24, Week 48
Number of Participants With Adverse Events Leading to Permanent Discontinuation of Study Intervention or Withdrawal
Time frame: Baseline through Week 48
The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data were collected and no analyses could be performed.
| Milestone | 15 mg LY3549492 | 60 mg LY3549492 | Placebo |
|---|---|---|---|
| Started | 0 | 1 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 1 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected/assessed in this study. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 15 mg LY3549492 | — | — | — |
| 60 mg LY3549492 | — | — | — |
| Placebo | — | — | — |
All enrolled participants.
| Age, Categorical(Participants) | 15 mg LY3549492 | 60 mg LY3549492 | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | 15 mg LY3549492 | 60 mg LY3549492 | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | 15 mg LY3549492 | 60 mg LY3549492 | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 15 mg LY3549492 | 60 mg LY3549492 | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 1 | 0 | 1 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2025 to primary completion in Aug 2025, 0 months.
Results were first posted in Sep 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naperiglipron